Kidney Cancer Weekly

November 17, 2025

Videos

Peer-to-Peer Clinical Conversations

LenCabo Phase II Trial Investigates Lenvatinib-Everolimus vs Cabozantinib in Relapsed Kidney Cancer - Andrew Hahn

Andrew Hahn

Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 checkpoint inhibitors.

Feasibility of Using an RNA-Seq Biomarker to Assign Therapy in the OPTIC RCC Trial - Pedro Barata

Pedro Barata

Pedro Barata discusses the OPTIC RCC trial, which uses RNA-sequencing biomarkers to guide treatment selection in metastatic clear cell renal cell carcinoma.

Beyond the Abstracts

Role of Radiotherapy in the Management of Primary Renal Cell Carcinoma: Recommendations from the Société Française De Radiothérapie Oncologique (SFRO, the French Society for Radiation Oncology) - Beyond the Abstract

Intermediate-Term Oncologic Outcomes of Partial Nephrectomy versus Cryoablation in Renal Tumors >3 cm: A Propensity Score Matched Analysis - Beyond the Abstract

Conference Coverage

ESMO 2025: The Intratumor Mycobiome Promotes Clear Cell Renal Cell Carcinoma Progression via Neutrophil-Mediated Immune Suppression

ESMO 2025: Soluble MAdCAM-1 Predicts Outcomes in Patients with Metastatic Renal Cell Carcinoma: Results from Three Independent Clinical Trials

ESMO 2025: Discussant: Lymphocyte Activation Gene-3 (LAG3) Expression Patterns, Kidney Injury Molecule-1 (KIM-1) Levels, and Biomarkers of Response to First-Line Nivolumab plus Ipilimumab Therapy

ESMO 2025: Relevance of the CPS Score and Tumor Nephrectomy in the SUNNIFORECAST Trial Comparing Ipilimumab/nivolumab Versus Standard of Care in Non-Clear Cell Renal Cell Cancer

ESMO 2025: [68Ga]Ga-DPI-4452 PET/CT for Staging of Patients with Clear Cell Renal Cell Carcinoma

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Advances in Diagnosis, Prognosis, and Treatment of Renal Cell Carcinoma.

Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study.

Role of Radiotherapy in the Management of Primary Renal Cell Carcinoma: Recommendations from the Société Française De Radiothérapie Oncologique (SFRO, the French Society for Radiation Oncology) - Beyond the Abstract

Pre-treatment C-reactive protein level is a prognostic marker of patients treated with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis.

Propensity Score-Matched Analysis of Neoadjuvant vs. Adjuvant Therapy in Renal Cell Carcinoma.

Real-World Experience With Lenvatinib Plus Everolimus (LEN+EVE) in Patients With Pretreated Advanced Renal Cell Carcinoma (RELEVANCE): A Retrospective, Multicenter Case Series.

Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study).

Robotic vs. open partial cytoreductive nephrectomy in metastatic renal cell carcinoma: adverse in-hospital outcomes.

Tumour sampling conditions perturb the metabolic landscape of clear cell renal cell carcinoma.

Tyrosine Kinase Inhibitors Outperform Immune Checkpoint Inhibitors in Bone-Predominant Metastatic Renal Cell Carcinoma: A Multicenter Real-World Analysis.

Contemporary assessment of diagnostic performance and histologic concordance of renal mass biopsy with surgical pathology.

Heterogeneous expression of BMP7, HIF-2α, Ki-67, and E-Cadherin in clear cell renal carcinoma: Prognostic implications based on tumor region.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC